Google Correlate has been launched on Google Labs. Users can now upload their own data series and retrieve a list of search terms based on popularity to see what best corresponds with a real world trend.
In the example below, official flu activity data were uploaded from the U.S. CDC over the last several years. The data reveal that people search for terms like [cold or flu] in a pattern similar to actual flu rates. Finding these correlated terms, a Google Flu Trends graph was built.
Users can also enter search terms such as [ribosome] and find other terms with activity that correspond well over time.
A white paper describes the methodology behind Google Correlate. How can Google help with the flu? Find out here.
Showing posts with label google. Show all posts
Showing posts with label google. Show all posts
Wednesday, June 1, 2011
Friday, February 19, 2010
Tuesday, May 5, 2009
The next Big Thing - Friend Feed
Paul Buchheit built the first version of Gmail in one day. Then he built the first prototype of Google's contextual advertising service Adsense, in one day as well. Now he's working on a much-watched startup called FriendFeed that he believes just brought to market the next big form of communication online: flowing, multi-person, real-time conversations.
"The open, realtime discussions that occur on FriendFeed," he says, "are going to become a major new communication medium on the same level as email, IM and blogging." That's a pretty ambitious claim, but Buchheit has the credibility to make it.
Things are changing fast at FriendFeed. Buchheit says that the company believes aggregation to be less important than real time conversation. "The open, realtime discussions that occur on FriendFeed are going to become a major new communication medium on the same level as email, IM and blogging. The aggregation component of FriendFeed is a convinient feature and a component of that openness, but not as central as the discussions."
Do you buy that? I'm not sure. But if anyone can lead the charge against incumbent technologies with a new paradigm that combines powerful richness and ease of use - Paul Buchheit might be that person. He did it with Gmail, now time will tell if he can do it with FriendFeed.
"The open, realtime discussions that occur on FriendFeed," he says, "are going to become a major new communication medium on the same level as email, IM and blogging." That's a pretty ambitious claim, but Buchheit has the credibility to make it.
Things are changing fast at FriendFeed. Buchheit says that the company believes aggregation to be less important than real time conversation. "The open, realtime discussions that occur on FriendFeed are going to become a major new communication medium on the same level as email, IM and blogging. The aggregation component of FriendFeed is a convinient feature and a component of that openness, but not as central as the discussions."
Do you buy that? I'm not sure. But if anyone can lead the charge against incumbent technologies with a new paradigm that combines powerful richness and ease of use - Paul Buchheit might be that person. He did it with Gmail, now time will tell if he can do it with FriendFeed.
Wednesday, March 18, 2009
GENE TESTING TO FIND A CURE FOR PARKINSON'S
23andMe, the gene-testing company backed by Google Inc., wants to collect DNA from the spit of 10,000 people with Parkinson’s disease to hunt for common genes that may cause the illness or predict patients’ response to drugs.
To entice patients to participate, the Mountain View, California-based company will offer to test them for $25, a fraction of the normal $399 fee. The quest is personal for Ann Wojcicki, who helped start 23andMe in 2006. Her husband, Google co-founder Sergey Brin, has a gene variant that increases his risk of developing the neurological condition, which afflicts his mother.
One million North Americans and more than 4 million people worldwide have Parkinson’s, which causes people to tremble, shake and lose control of their body’s movements. The condition comes in different forms, and its causes are poorly understood, with a handful of genes known to increase the risk. 23andMe hopes to uncover others.
23andMe, a closely held company, is working with two nonprofit research groups, the Parkinson’s Institute in Sunnyvale, California, and the New York-based Michael J. Fox Foundation, which was founded in 2000 by Fox, an actor, who suffers from Parkinson’s.
In addition to genes, environmental factors including chemical exposure and drug use may also play a role in development of the illness. “We want to try and find out if there are other genetic variations that are associated with Parkinson’s or with rapid progression or slow progression,” said Wojcicki, in a telephone interview yesterday. “Also, why some people respond well to therapy, some people don’t, and some develop resistance faster.”
“We’re very frustrated with the pace of research discoveries and we felt one way to accelerate it would be to empower individuals and form communities and self-create a research cohort,” she said. “We also believe we are really democratizing research in a new way.”
Google invested about $3.9 million in 23andMe in 2007. Brin is helping to subsidize the reduced cost for the gene-testing that gets performed for each patient, Wojcicki said. 23andMe wouldn’t disclose the extent of his contribution.
To entice patients to participate, the Mountain View, California-based company will offer to test them for $25, a fraction of the normal $399 fee. The quest is personal for Ann Wojcicki, who helped start 23andMe in 2006. Her husband, Google co-founder Sergey Brin, has a gene variant that increases his risk of developing the neurological condition, which afflicts his mother.
One million North Americans and more than 4 million people worldwide have Parkinson’s, which causes people to tremble, shake and lose control of their body’s movements. The condition comes in different forms, and its causes are poorly understood, with a handful of genes known to increase the risk. 23andMe hopes to uncover others.
23andMe, a closely held company, is working with two nonprofit research groups, the Parkinson’s Institute in Sunnyvale, California, and the New York-based Michael J. Fox Foundation, which was founded in 2000 by Fox, an actor, who suffers from Parkinson’s.
In addition to genes, environmental factors including chemical exposure and drug use may also play a role in development of the illness. “We want to try and find out if there are other genetic variations that are associated with Parkinson’s or with rapid progression or slow progression,” said Wojcicki, in a telephone interview yesterday. “Also, why some people respond well to therapy, some people don’t, and some develop resistance faster.”
“We’re very frustrated with the pace of research discoveries and we felt one way to accelerate it would be to empower individuals and form communities and self-create a research cohort,” she said. “We also believe we are really democratizing research in a new way.”
Google invested about $3.9 million in 23andMe in 2007. Brin is helping to subsidize the reduced cost for the gene-testing that gets performed for each patient, Wojcicki said. 23andMe wouldn’t disclose the extent of his contribution.
Subscribe to:
Posts (Atom)